- Home
- BHC vs IMCR Comparison
BHC vs IMCR Comparison
Compare BHC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- IMCR
- Stock Information
- Founded
- BHC N/A
- IMCR 2008
- Country
- BHC Canada
- IMCR United Kingdom
- Employees
- BHC N/A
- IMCR N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHC Health Care
- IMCR Health Care
- Exchange
- BHC Nasdaq
- IMCR Nasdaq
- Market Cap
- BHC 1.7B
- IMCR 1.5B
- IPO Year
- BHC N/A
- IMCR 2021
- Fundamental
- Price
- BHC $4.53
- IMCR $36.60
- Analyst Decision
- BHC Hold
- IMCR Buy
- Analyst Count
- BHC 5
- IMCR 10
- Target Price
- BHC $7.20
- IMCR $58.13
- AVG Volume (30 Days)
- BHC 1.5M
- IMCR 440.3K
- Earning Date
- BHC 04-30-2025
- IMCR 05-07-2025
- Dividend Yield
- BHC N/A
- IMCR N/A
- EPS Growth
- BHC N/A
- IMCR N/A
- EPS
- BHC N/A
- IMCR N/A
- Revenue
- BHC $9,731,000,000.00
- IMCR $333,581,000.00
- Revenue This Year
- BHC $3.71
- IMCR $25.96
- Revenue Next Year
- BHC $5.03
- IMCR $8.06
- P/E Ratio
- BHC N/A
- IMCR N/A
- Revenue Growth
- BHC 8.53
- IMCR 25.75
- 52 Week Low
- BHC $3.96
- IMCR $23.15
- 52 Week High
- BHC $9.85
- IMCR $49.05
- Technical
- Relative Strength Index (RSI)
- BHC 39.91
- IMCR 71.46
- Support Level
- BHC $4.50
- IMCR $31.14
- Resistance Level
- BHC $4.61
- IMCR $33.30
- Average True Range (ATR)
- BHC 0.13
- IMCR 1.94
- MACD
- BHC 0.03
- IMCR 0.57
- Stochastic Oscillator
- BHC 21.30
- IMCR 96.12
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.